Satelite Symposia

Monday, 18 February

12:00 – 13:15 Schwarzhorn

Satellite Symposium Amgen (a lunch bag will be offered)

PCSK9 Inhibition: Translation of FOURIER into Clinical Practice

Chairperson :
T. F. Lüscher, London

12:00 – 12:00

Genetic evidence for the efficacy of PCSK9 inhibition

A. L. Catapano, Milan
12:00 – 12:00

Familial hypercholesterolemia and PCSK9 mutation in patients with ACS

12:00 – 12:00

FOURIER: What does it mean for clinical practice?
Are very low cholesterol levels safe?

F. Mach, Geneva
12:00 – 13:15 Seehorn

Update Session Bayer (lunch buffet will be offered)

The horizon of vascular protection and beyond

Chairpersons :
J. E. Deanfield, London
M. Valgimigli, Berne

12:00 – 12:25

The rise of NOACS in stroke prevention for patients with AFib

A. J. Camm, London
12:25 – 12:50

The rationale for combined platelet and coagulation inhibition

P. G. Steg, Paris
12:50 – 13:15

COMPASS: The new direction in vascular protection

S. Yusuf, Hamilton
18:00 – 18:30 Davos 2

Satellite on the Spot Pfizer

How to recognize your cardiac amyloidosis patient

Chair:
A. V. Kristen, Heidelberg

18:00 – 18:10

What is cardiac amyloidosis?

G. Noll, Zurich
18:10 – 18:20

Diagnostic pathway and red flags

S. Stämpfli, Lucerne
18:20 – 18:30

Recognizing & reaching a differential diagnosis of transthyretin cardiac amyloidosis

A. V. Kristen, Heidelberg